Moreover, CDK4/6 inhibitors are currently being explored for other tumor types, and these are each likely to have novel resistance mechanisms (Parreno et al., 2022; Klein et al., 2018; Knudsen and Witkiewicz, 2017). The gene discussed is CDK4; the disease is neoplasm.